Intage : Explanation Materials for Consolidated Financial Results for the Six Months Ended September 30, 2017
November 27, 2017 at 05:48 am EST
Share
Financial results presentation for institutional investors and analysts
Explanation Materials for Consolidated Financial Results for the Six Months Ended September 30, 2017
November 16, 2017
Security code: 4326
Contents
Results for the Six Months Ended September 30, 2017
Status Report on the 12th Medium-Term Management
Plan
Summary of Consolidated Statements of Income
As initially projected, net sales increased but operating income declined. Ordinary income and net income attributable to owners of parent grew from the same period of the previous year and were higher than forecasts owing to an increase in non-operating income (mainly dividend income).
*On November 10, 2017, the Notice Regarding Difference between Interim Forecasts for the Fiscal Year Ending March 31, 2018 and Actual Results and Revision of Full-year Forecasts was released.
(¥ million)
Six months ended Sept.
30, 2016
Six months ended Sept.
30, 2017
Y/Y
Forecasts
Compared to forecasts
Net sales
21,448
22,941
+7.0%
23,000
-0.3%
Operating income
1,373
1,270
-7.5%
1,100
+15.5%
Ordinary income
1,370
1,469
+7.2%
1,100
+33.5%
Net income attributable to owners of parent
914
1,008
+10.3%
700
+44.1%
EPS (Yen)
22.90
25.25
ROA (%)
2.5
2.6
(Note) A 2-for-1 stock split of the Company's outstanding shares of common stock implemented on October 1, 2017 is factored into EPS figures.
Summary of Consolidated Balance Sheets and Consolidated Statements of Cash Flows (¥million)
Summary of Consolidated Balance Sheets
Year ended Mar. 31,
2017
Six months ended Sept. 30, 2017
Increase/ Decrease
Remarks
Current assets
25,694
24,309
-1,384
Due to decreased notes and accounts receivable-trade
Non-current assets
13,373
13,421
+48
Mainly due to increased investment securities and decreased property, plant and equipment
Total assets
39,067
37,731
-1,336
Current liabilities
11,999
10,543
-1,456
Mainly due to decreased accounts payable-trade and income taxes payable
Non-current liabilities
3,295
3,302
+6
Total liabilities
15,295
13,845
-1,450
Total shareholders' equity
22,462
22,588
+126
Total net assets
23,771
23,886
+115
Summary of Consolidated Statements of Cash Flows
Six months ended Sept. 30, 2016
Six months ended Sept. 30, 2017
Increase/ Decrease
Remarks
Cash flows from operating activities
2,073
1,781
-291
Due to increased payments of notes and accounts payable- trade
Cash flows from investing activities
-1,038
-721
+316
Due to increased payments for purchase of investment securities and decreased payments for purchase of property, plant and equipment
Cash flows from financing activities
-756
-980
-223
Due to purchase of investments in subsidiaries that do not result in change in scope of consolidation
Effect of exchange rate changes on cash and cash equivalents
-143
1
+145
Net increase/decrease in cash and cash equivalents
134
81
-53
Cash and cash equivalents at beginning of period
9,812
10,418
+605
Cash and cash equivalents at end of period
9,947
10,499
+552
Intage Holdings Inc. published this content on 27 November 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 November 2017 10:46:09 UTC.
Original documenthttp://irvision2next.blob.core.windows.net/4326/ir/12518904896199999999_c53b9056-dc00-4a8e-bdf9-d05623ea3f64.pdf
Public permalinkhttp://www.publicnow.com/view/A492A92DBC0FEA06196181B85073AF6256E6B3F7
INTAGE HOLDINGS Inc., formerly INTAGE Inc., is a provider of marketing research and consulting services. The Market Research and Consulting segment is engaged in marketing research operations, including customer panel research, retail shop panel research and other research activities; customized research services, including Internet research, mail survey, visiting interview survey and qualitative research, as well as the provision of related consulting services. The System Solution segment is engaged in the development and sale of software, the operation of systems and data centers, and the provision of various related consulting services. The Drug Development Support segment is engaged in the contract research organization (CRO) business. As of March 31, 2014, the Company had 24 subsidiaries and one associated company.